http://genengnews.com/insight-and-intelligence/top-8-biopharma-clusters-in-asia/77900082
"Top 8 Biopharma Clusters in Asia"
-
#8. Malaysia
"Next year marks 10 years since the country established its National
Biotechnology Policy aimed at growing the industry into a 5% contributor
to GDP by 2020. With six years to go, Malaysia has some
accomplishments—including its number of companies (seventh with 200 as
of 2012), thanks in part to the BioNexus incentives program. A Malaysian
billionaire, Genting Group Chairman Tan Sri Lim Kok Thay, is lead
investor in J. Craig Venter’s Human Longevity, which vows to assemble
the world’s largest human gene sequencing operation. And on Wednesday,
Indonesian-based Kimia Farma said it will expand its Malaysian presence
beyond a single dispensary in Sepang: 'The number will increase. Our
sales in Malaysia have continued to increase,' corporate secretary Djoko
Rusdianto told Antara News. Malaysia also placed eighth in patents
(1,190) and R&D spending ($4.953 billion in 2011)."
-
#7. Singapore
"The dazzling Biopolis that anchors Singapore’s biopharma industry
reflects how far the multi-ethnic city-state has come in building one of
Asia’s fastest-growing industry clusters. Singapore hosts many of the
largest industry giants including, Bayer, GlaxoSmithKline, Novartis, and
Roche, which account for many of its biopharma jobs (37,735 in 2012).
The country is sixth in venture capital ($17.7 million to three
companies), and sixth in patents (3,068), but lower in number of
companies (eighth at 95 as of 2012), and R&D (seventh at $6.987
billion, of which more than $1.5 billion is for biomedical
research)—though considerable research activity occurs at 30
public-sector institutes under the Agency for Science, Technology and
Research (known as A*STAR) and the Ministry of Health."
-
#6. Australia
"Despite embracing biopharma later than many Asian countries, Australia
is actually second in the number of biotech and pharma patents (10,599),
and fourth in number of companies (527 in 2011). The country saw
investors flock to biopharma following the collapse of gold prices and
an imploding mining sector, boosting both giants like ASX and new
launches: 'How biotech finally boomed,' the Sydney Morning Herald
headlined a feature on the industry in January. Australia ranked fifth
in venture capital awards ($26.1 million to five companies) and sixth in
IPOs ($6.8 million to Algae Tec in 2011). The land Down Under is also
sixth in R&D spending (about $20.5 billion in 2010) but lags in
number of jobs (13,000 as of last year)."
-
#5. Taiwan
"Officials have set their sights on growing biotech for some two
decades, and since 2007 have passed three laws designed to improve the
business climate, joining with private funds to raise more than $2
billion for startups. One priority has been government R&D funding,
where Taiwan ranked fourth by spending about $27.5 billion. That spend
has helped build jobs (19,332 in 2011) and homegrown businesses, where
Taiwan ranks fourth in IPOs ($25.1 million to a single company, Taiwan
Liposome in 2012) and sixth in number of companies (400 in 2011). The
country ranked seventh in both patents (2,281) and 2013–14 venture
capital, thanks to the $17 million won by Senhua Biosciences in
December."
-
#4. South Korea
"Taking office last year, President Park Geun-hye excited biopharma
industry leaders with her vision of a 'second miracle on the Han River.'
The first was the transformation of the country a generation ago into
an economic powerhouse by tying manufacturing with growth in several
tech sectors—including biopharma, where South Korea shines in number of
existing companies (second at 857 in 2010) and R&D spending (third
at $65.394 billion in 2012). Earlier this month, Sanofi Pasteur said it
will join homegrown SK Chemical to build a pneumococcal conjugate
vaccine plant in Angdong. Domestic public company growth has stayed
steady; South Korea finished fourth in patents (8,739) and fifth in IPOs
($17.5 million raised by a single company, Seegene) but startups lag,
judging from a dearth of 2013–14 venture capital awards."
-
#3. India
"FDA Commissioner Margaret A. Hamburg, M.D., tried to balance criticism
of some Indian drug manufacturers with praise for the country’s progress
in building one of Asia’s biggest biopharma clusters with some 50,000
jobs (as of last year) during her recent trip to the subcontinent. Yet
these days, even some industry professionals are critical; Krishna Ella,
CMD of Bharat Biotech, complained: 'Students who graduate do not even
know how to handle lab equipment sometimes.' India’s strengths are in
company growth, ranking second in VC activity (more than $66 million to
four companies) and fourth in IPOs (thanks to Claris Lifesciences
raising $80 million in 2010). However, the country is fifth in both
number of companies (about 500 as of last year) and at least fifth in
R&D spending (figures range from $24.3 billion in 2007 to an
estimated $40 billion in 2012), as well as fifth in patents (4,793)."
-
#2. Japan
"The Land of the Rising Sun may soon be eclipsed in biopharma by China,
whose great leap forward over a generation contrasts with Japan’s
economic stagnation. Prime Minister Shinzo Abe vows to grow a biotech
industry alongside the legacy cluster of pharma giants, in part by
speeding up decisions on new drugs and stepping up R&D spending; the
nation will soon consolidate three agencies into a single research
funding source akin to the U.S. NIH. Japan trails China in overall
R&D funding (second at $151.8 billion in 2012); biomed R&D
numbers vary wildly. There’s no question Japan’s on top in patents
(39,797) and recent IPOs (nine companies raising $2.636 billion)—though
the IPO figure was skewed by Otsuka Holdings’ $2.4 billion offering in
2010—while Japan finished third in companies (538 in 2011) and fourth in
venture capital ($47.1 million to four companies)."
-
#1. China
"China didn’t grant patents until 1984, and didn’t issue patents for
biopharma inventions until eight years later. That explains why the
world’s most populous nation, which is at or near the top in many of
GEN’s cluster criteria, places only third in biotech and pharma patents
with 9,302. In the decades that have followed, China has caught up
impressively in biopharma, leading Asia in R&D spending ($160
billion biomedical of a $243.4 billion recorded by OECD), companies
(7,500 as of last year), jobs (more than 250,000 as of last year), and
venture capital ($73.9 million to five companies), while coming in
second to Japan in IPOs (just under $2.1 billion raised by an
Asian-leading 14 companies). Years of massive government spending on
research explains why, as does a domestic pharma-and-herbal medicine
sector growing with global biopharma giants, many drawn by
lower-than-Western labor costs."
|
Articles
Aucun commentaire:
Enregistrer un commentaire